---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-026270"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:04:38.373154+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Unicycive reports FY 2024 net loss of $37.8M; OLC NDA under FDA review with PDUFA June 28, 2025

## Summary
- Net loss attributable to common stockholders $37.8M or $0.56 per share, vs $31.4M ($1.28) in 2023.
- Cash and cash equivalents $26.1M as of Dec 31, 2024; company expects to fund operations into 2026.
- R&D expenses rose to $20.0M from $12.9M YoY; G&A expenses $12.1M vs $8.5M.
- FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.
- Commercial planning underway for anticipated OLC launch in late 2025 if approved.

## SEC filing metadata
- accession: 0001213900-25-026270
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/0001213900-25-026270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea0236324-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-026270
- JSON: https://secwatch.observer/filing/0001213900-25-026270.json
- Plain text: https://secwatch.observer/filing/0001213900-25-026270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.